Loss of Nrf2 has been shown to enhance susceptibility to neoplasm formation from the action of chemical carcinogens [21,22], while agents that induce Nrf2 expression dramatically reduce susceptibility to carcinogenesis [23] and are thus an emerging therapeutic target. The gene discussed is NFE2L2; the disease is neoplasm.